Proactive Investors - Run By Investors For Investors

Ventripoint Diagnostics shares pump after positive findings from sarcoidosis study in Netherlands using VMS

Pulmonary hypertension occurs in 6% to 74% of patients with sarcoidosis ...
Ventripoint Diagnostics shares pump after positive findings from sarcoidosis study in Netherlands using VMS
Cardiac specialists at the hospital in the Netherlands are using the med-tech group's VMS system

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCMKTS:VPTDF) revealed its VMS heart monitoring system was again proving its worth - after positive results from the St Antonius Hospital in the Netherlands, sending shares in the company higher.

Cardiac specialists there are using the med-tech group's VMS system to study patients with sarcoidosis, an inflammatory disease, which affects multiple organs in the body, including the heart.

READ: Ventripoint says Johns Hopkins doctor cited VMS+ heart analysis system’s clinical feasibility at Milan conference

The cause of Sarcoidosis is unknown and affects about 50,000 people a year in the US. Between 150,000 and 200,000 people have chronic sarcoidosis.

Pulmonary hypertension occurs in 6% to 74% of patients with sarcoidosis. This is a serious complication leading to early death.

Around 500 sarcoidosis patients have been studied at the Dutch hospital so far. The focus is on the early detection of pulmonary hypertension.

The study has found almost 20 patients with confirmed pulmonary hypertension and the cardiac team will continue to monitor the right-ventricular function of these patients, using the Ventripoint solution, to better understand the progress of the disease.

"The right heart is difficult to assess, and in patients with pulmonary disease, this challenge is even more difficult," said Dr Marloes Huitema, MD Cardiology at St. Antonius Hospital.

"Ventripoint provides a solution that allows us to overcome these barriers and might be an alternative to MRI, which is costly, time consuming and not possible for all patients.

"Furthermore, in those patients with pulmonary hypertension, the Ventripoint technology gives us an ability to repeatedly evaluate the right-ventricular dimensions with a rapid, inexpensive, non-invasive procedure to determine therapeutic efficacy."

Ventripoint noted that there were many potential applications for its VMS technology; providing confidence in the volumetric measurements of patients with accuracy comparable to cardiac MRI (magnetic resource imaging) is its strength.

The group's VMS Plus heart monitoring technology measures whole heart function using conventional ultrasound.

The company has developed a suite of applications for all major heart diseases and wants to commercialize the technology to improve heart care.

Shares in Toronto added almost 12% to $0.19.

Contact Giles at [email protected]

Follow him on Twitter @ Gile74

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

Social media use
April 18 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use